BLAINJECTIONINJECTABLE
Approved
Aug 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
4/8 — Partial
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENSPRYNG (satralizumab) is a monoclonal antibody (MAb) therapeutic approved by the FDA on August 14, 2020, for treating neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD). The drug is administered via injection and works by targeting interleukin-6 signaling pathways to suppress autoimmune inflammation in rare neurological conditions. ENSPRYNG addresses a significant unmet need in rare neuroimmunological disorders where limited treatment options previously existed, positioning itself as a key therapeutic option for patients with severe autoimmune CNS disease.
$0.0BPart D
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
Started Apr 2026
8 enrolled
Neuromyelitis Optica Spectrum DisorderNMOSD
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
Started Apr 2025
30 enrolled
Duchenne Muscular Dystrophy
Satralizumab in Aneurysmal Subarachnoid Hemorrhage
Started Jun 2024
0Aneurysmal Subarachnoid HemorrhageDelayed Cerebral Ischemia
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
Started Nov 2023
127 enrolled
Thyroid Eye Disease
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
Started Oct 2023
131 enrolled
Thyroid Eye DiseaseTED
Worked on ENSPRYNG at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.